-

Flatiron Health Joins Veeva’s Product Partner Program to Accelerate Oncology Clinical Research

Partnership enhances oncology clinical trial efficiency through streamlined technology integration and long-term strategic collaboration.

NEW YORK--(BUSINESS WIRE)--Flatiron Health, a healthtech company transforming clinical research through solutions that integrate research into everyday care, today announced they will partner with Veeva Systems, a global leader in cloud software for the life sciences industry. As part of the partnership, Flatiron Health will join the Veeva Product Partner Program.

Flatiron and Veeva customers utilizing Flatiron Clinical Pipe™ will benefit from accelerated deployment and continually optimized configurations, ensuring seamless performance and a well-supported experience to meet evolving needs.

Share

This collaboration builds on the integration of Flatiron Clinical Pipe™ and Veeva EDC (Electronic Data Capture), enhancing value and experience for both research sites and sponsor customers. As a cutting-edge EHR-to-EDC connector, Flatiron Clinical Pipe™ eliminates manual data entry of structured and unstructured data—improving site workflows, lowering data monitoring costs, and accelerating study timelines. Through this partnership, Flatiron and Veeva customers utilizing Flatiron Clinical Pipe™ will benefit from accelerated deployment and continually optimized configurations, ensuring seamless performance and a well-supported experience to meet evolving needs.

“Our collaboration with Veeva strengthens Flatiron’s ecosystem of partners in clinical research, reinforcing our position as an innovator in the use of technology to streamline clinical trials,” said Alex Deyle, General Manager of Clinical Research at Flatiron Health. “Flatiron Clinical Pipe, integrated with Veeva EDC, enables more streamlined data acquisition for clinical trials across a broader set of both research sites and sponsors—ultimately reducing burden, driving operational efficiencies, and accelerating research timelines.”

Additionally, the partnership establishes a long-term forum for strategic collaboration, allowing both companies to align on future innovations that streamline clinical trial data acquisition and drive greater value for customers.

Research published in the journal ESMO Real World Data and Digital Oncology, found that clinical research teams using Flatiron Clinical Pipe™ were able to accurately transfer thousands of data points, representing completion of hundreds of case report forms (CRF), with the average time of 37 seconds for a user to launch, complete, and submit a CRF, representing significant time savings for data entry over the course of a trial.1 Data transferred to the EDC with Flatiron Clinical Pipe™ completely mirrors source data in the EHR, reducing the need for source data verification on transferred data, allowing for greater efficiency for study teams.

About Flatiron Health
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @FlatironHealth

  1. Utility of automated data transfer for cancer clinical trials and considerations for implementation. Pfeffer, M. et al. ESMO Real World Data and Digital Oncology, Volume 7, 100112. DOI: 10.1016/j.esmorw.2025.100112

 

Contacts

Flatiron Health
Nina Toor
press@flatiron.com

Flatiron Health

Details
Headquarters: New York, NY
CEO: Carolyn Starrett
Employees: 2,500
Organization: PRI

Release Versions

Contacts

Flatiron Health
Nina Toor
press@flatiron.com

Social Media Profiles
More News From Flatiron Health

CORRECTING and REPLACING Flatiron Health Announces Research to Be Presented at ASCO 2025

NEW YORK--(BUSINESS WIRE)--Please remove the partners listed under "Real-world (rw) ctDNA testing trends and associated outcomes in patients (pts) with early stage breast cancer (EBC)." The updated release reads: FLATIRON HEALTH ANNOUNCES RESEARCH TO BE PRESENTED AT ASCO 2025 Flatiron’s 2025 ASCO research showcases the power of longitudinal, real-world oncology data and innovative AI-driven methodologies to generate actionable evidence, address health equity, and accelerate progress in cancer c...

Flatiron Health Announces Research to Be Presented at ISPOR 2025

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its presence at ISPOR—The Professional Society for Health Economics and Outcomes Research 2025 Conference, set to take place May 13-16 in Montreal, QC, Canada. Flatiron’s real-world data is featured across 15+ pieces of research to be presented at the conference, including eight Flatiron authored research posters. Additionally, Flatiron will participate in a panel discussion on the role of real-world evidence in precision medicine, incl...

Flatiron Health Announces Strategic Partnership with Massive Bio to Enhance Patient Identification Capabilities and Services

NEW YORK--(BUSINESS WIRE)--Flatiron Health, a healthtech company transforming clinical research through technology that integrates research into everyday care, today announced a strategic partnership with Massive Bio, global leader in using artificial intelligence to streamline patient identification and recruitment for clinical trials, to expand patient identification capabilities and improve clinical trial enrollment across the U.S. “Flatiron Health is excited to join forces with Massive Bio,...
Back to Newsroom